Latest Breaking News On - Regulatory affairs at tracon pharmaceuticals inc - Page 1 : comparemela.com

Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation fr

With a Focus on Potential Pivotal Studies in 2025, Treadwell has Strengthened its Leadership Team by Appointing Brenda Marczi, PharmD, MBA as SVP and Head of Regulatory AffairsTORONTO & SAN FRANCISCO (BUSINESS WIRE) Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advanc.

United kingdomBrenda marcziRoger sidhuUniversity of pennsylvaniaRutgers universityRegulatory affairs at tracon pharmaceuticals incUniversity of marylandDrug administrationLeadership teamHead of regulatory affairsRegulatory affairs at treadwellPotential pivotal studiesAppointing brenda marcziTreadwell therapeuticsDrug actSenior vice president

Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U S FDA for the Treatment of Acute Myeloid Leukemia

Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U S FDA for the Treatment of Acute Myeloid Leukemia
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomBrenda marcziRoger sidhuDrug administrationRegulatory affairs at tracon pharmaceuticals incProduct serviceRegulatory affairs at treadwellRutgers universityHead of regulatory affairsUniversity of marylandUniversity of pennsylvaniaAnnounces ocifisertibReceived orphan designationAcute myeloidDrug actSenior vice president